The benzodiazepines flunitrazepam, diazepam, and Ro 15-1788 
GABA is the major inhibitory neurotransmitter within the CNS (Rabow et al. 1995) . Its actions are mediated via the ionotropic GABA A and GABA C receptors and the metabotropic GABA B receptor. To date, sixteen ionotropic GABA receptor subunit genes have been identified ( ␣ 1-6 , ␤ 1-3 , ␥ 1-3 , ␦ , 1-2 , and ⑀ ), with further diversity being introduced by the presence of alternatively spliced forms of certain of these subunits (Lüddens et al. 1995; Stephenson 1995; Davies et al. 1997; Whiting et al. 1997) . Of these subunit genes, the 1-2 subunits constitute the GABA C receptor, which is found in the retina and arguably various regions of the brain (Johnston 1996) ; whereas, the GABA A receptor is generally considered to be a pentamer of ␣ , ␤ , and ␥ subunits, with the role of the ␦ and ⑀ subunits being poorly understood (Lüddens et al. 1995; Stephenson 1995; McKernan and Whiting 1996; Davies et al. 1997; Whiting et al. 1997) .
The GABA A receptor and its molecular structure and pharmacology has attracted considerable attention in view of it being the site of action of a number of compounds that can affect receptor function (i.e., chloride ion flux) either directly, by binding at the GABA site or within the ion channel, or indirectly, by binding to allosteric modulatory sites. Included in this latter class of compounds are the benzodiazepines, neurosteroids, barbiturates (such as pentobarbital), the anticonvulsant loreclezole, and some anesthetics (for example, etomidate and alphaxalone) (Sieghart 1995) . Of these allosteric sites, the binding site for benzodiazepines has been most intensively studied, because of it's clinical relevance in mediating the anxiolytic, anticonvulsant, sedative-hypnotic, and muscle relaxant effects of such drugs as chlordiazepoxide, diazepam, and flunitrazepam.
A number of pharmacologically distinct benzodiazepine binding sites can be identified on the basis of their affinities for the "classical" benzodiazepines, such as diazepam and flunitrazepam, as well as the atypical benzodiazepines 2-oxoquazepam and Ro 15-4513 and nonbenzodiazepines, such as the triazolopyridazine CL 218,872, the imidazopyridine zolpidem, the ␤ -carboline methyl ␤ -carboline-3-carboxylate ( ␤ -CCM) and the cyclopyrrolones zopiclone and suriclone (Lüddens et al. 1995) . The characterization of various cloned GABA A receptors expressed in either Xenopus oocytes or mammalian cells has defined the molecular basis of this pharmacological diversity (Rabow et al. 1995; Sieghart 1995) . Hence, the benzodiazepine binding site requires the presence of an ␣ and a ␥ subunit, with the pharmacology of the binding site of physiologically relevant GABA A receptors being determined largely by the type of ␣ subunit present (Rabow et al. 1995; Sieghart 1995; McKernan and Whiting 1996) .
More specifically, the ␣ 4 or ␣ 6 subunit renders GABA A receptors insensitive to "classical" benzodiazepines, such as diazepam. With respect to diazepamsensitive GABA A receptors, the presence of an ␣ 1 subunit confers high affinity for CL 218,872 and zolpidem; whereas, ␣ 5 subunit-containing GABA A receptors have essentially no affinity for zolpidem. Receptors containing either an ␣ 2 or ␣ 3 subunit possess an intermediate affinity for zolpidem (Lüddens et al. 1995; Rabow et al. 1995; Sieghart 1995; McKernan and Whiting 1996) . This pharmacological diversity is further exacerbated by the neuroanatomical heterogeneity of the distribution of these different GABA A receptor subtypes. Thus, although the cortex and hippocampus contain ␣ 1 , ␣ 2 , ␣ 3 , ␣ 4 , and ␣ 5 subunits, more restricted localizations are found in the cerebellum (primarily ␣ 1 and ␣ 6 ), spinal cord (primarily ␣ 2 and ␣ 3 ), and thalamus (primarily ␣ 1 and ␣ 4 ) (Wisden et al. 1991 (Wisden et al. , 1992 Fritschy and Mohler 1995) . Consistent with this anatomical distribution, in vitro pharmacological analysis of cerebellum and spinal cord GABA A receptors (Villiger 1984; Watanabe et al. 1985; Langer and Arbilla 1988; Benavides et al. 1988 Benavides et al. , 1992 suggests that the benzodiazepine pharmacology of the cerebellum and spinal cord are dictated largely by the ␣ 1 and ␣ 2 and ␣ 3 subunits, respectively.
The benzodiazepine binding site of ␣ 1 , ␣ 2 , ␣ 3 , and ␣ 5 subunit-containing GABA A receptors can be labeled in vivo using radiolabeled Ro 15-1788 (Goeders and Kuhar 1985; Potier et al. 1988a Potier et al. , 1988b Persson et al. 1985) . However, within the cerebellum, binding is predominantly to ␣ 1 subunit-containing GABA A receptors because although the cerebellum is the major site of ␣ 6 subunit expression in the brain, Ro 15-1788 has a low affinity for this subpopulation of receptors. In addition, although [ 3 H]Ro 15-1788 binds to the benzodiazepine site of GABA A receptors containing an ␣ 5 subunit, this population of receptors is expressed at relatively low levels throughout the brain as a whole, and in the cerebellum and spinal cord in particular (Fritschy and Mohler 1995; McKernan and Whiting 1996 The purpose of the present study was to establish whether the in vitro pharmacology of compounds relatively selective for GABA A receptors containing an ␣ 1 subunit, such as CL 218,872 and zolpidem, is reflected in vivo by differential occupancy in areas of the mouse CNS enriched in ␣ 1 (cerebellum) versus ␣ 2 and ␣ 3 (spinal cord) subunit-containing receptors. 
METHODS

Materials
In Vitro Radioligand Binding
The affinities of compounds binding at the benzodiazepine binding site of different ␣ subunit-containing human recombinant GABA A receptors were measured essentially as described elsewhere (Hadingham et al. 1993) . In brief, cells stably transfected with cDNA for the ␤ 3 and ␥ 2 and various ␣ subunits were harvested, and cell membranes prepared. Membranes (50 to 100 g protein) were incubated in the presence of varying concentrations of compound for 1 h at 4ЊC in assay buffer (10 mM potassium phosphate buffer containing 100 mM KCl, pH 7.4) containing [ 3 H]Ro 15-1788 (concentration in assay ϭ 1.8 nM for ␣ 1 and ␣ 2 and/or 1.0 nM ␣ 3 and ␣ 5 subunit-containing receptors) in a final assay volume of 0.5 ml. Non-specific binding was defined using 10 M flunitrazepam. The Ki values were calcu-
In Vivo Binding of [ 3 H]Ro 15-1788
The methods used were essentially those of Goeders and Kuhar (1985) as modified to include the separation of membrane-bound from unbound radioactivity (Potier et al. 1988a (Potier et al. , 1988b , although this separation of bound from free radioligand is not absolutely necessary (Facklam et al. 1992) . Mice were then killed at varying times (0.5 to 30 min) later, and the whole brain was removed, weighed, and rapidly homogenized in 10 volumes of ice-cold buffer (10 mM potassium phosphate buffer containing 100 mM KCl, pH 7.4). Aliquots of homogenate (200 l) were either added directly to scintillation vials (total radioactivity; i.e., unbound and membrane-bound) or were filtered over Whatman GF/B filters (membrane-bound radioactivity). These were rapidly washed with 10 ml of ice-cold buffer, following which the filters were placed in vials, scintillation fluid was added, and radioactivity was measured using a scintillation counter.
Inhibition of In Vivo [
3 H]Ro 15-1788 Binding. Compounds were made up as either a suspension in 0.5% carboxymethylcellulose (CMC) or in solution in 70% polyethyleneglycol 300 and were administered IP 30 min prior to killing; whereas, [ 3 H]Ro 15-1788 was given IV 3 min prior to killing. The cerebellum was then rapidly dissected from the brain, and the spinal cord was blown out of the spinal column using compressed air. Both tissues were weighed, rapidly homogenized, filtered, and counted as above.
Non-specific in vivo binding of [ 3 H]Ro 15-1788 was estimated by measuring the membrane-bound radioactivity in mice pretreated for 30 min with 30 mg/kg flunitrazepam. In these animals, the radioactivity in 200 l aliquots of homogenates of cerebellum and spinal cord (90 and 60 dpm, respectively) represented about 5% of the corresponding radioactivity seen in vehicletreated animals (2,800 and 1,200 dpm, respectively).
RESULTS
Benziodiazepine-Site Ligand Affinities
In vitro, diazepam, flunitrazepam, and DMCM show no appreciable selectivity for the benzodiazepine binding site of different ␣ subunit-containing GABA A receptors, with respective affinities across different recombinant GABA A receptors in the region of 10 to 20 nM, 2 to 5 nM, and 5 to 10 nM (Figure 1 ). In contrast, CL 218,872 and zolpidem had affinities for the ␣ 1 subunit-containing GABA A receptor of 57 and 27 nM, which represented a 6 to 34-fold and 14 to 20-fold selectivity for ␣ 1 versus ␣ 2 -and ␣ 3 -subunit-containing GABA A receptors for CL 218,872 and zolpidem, respectively. lower affinity for the different GABA A receptor subtypes than DMCM yet is fivefold more potent in vivo.
Reduction of In Vivo [ 3 H]Ro 15-1788 Binding by ␣ 1 -Selective Ligands
In contrast to nonselective compounds, the ␣ 1 -selective compounds CL 218,872 and zolpidem produced a greater reduction of in vivo [
3 H]Ro 15-1788 binding (i.e., occupancy) in the ␣ 1 subunit-enriched cerebellum as compared to the predominantly ␣ 2 /␣ 3 subunit-containing spinal cord (Figure 4) The relatively flat displacement curve for zolpidem in the spinal cord (Figure 3 ) is comparable to that seen in the mouse hippocampus (Benavides et al. 1988 ) and rat spinal cord (Benavides et al. 1992) , and presumably, it reflects the heterogeneity of GABA A receptors in these regions in contrast to the relatively homogeneous population of ␣ 1 subunit-containing benzodiazepine binding sites associated with cerebellar GABA A receptors.
DISCUSSION
The peak of both total and membrane-bound radioactivity was found to be 3 minutes after IV administration, in agreement with previous studies showing that [ 3 H]benzodiazepines rapidly enter the brain (Goeders and Kuhar 1985; Ciliax et al. 1986; Potier et al. 1988b ). The fact that more than 75% of the radioactivity in the brain is membrane bound suggests that the majority of [ 3 H]Ro 15-1788 that gets into the brain is available for binding to the receptor and is not sequestered in pools unavailable for receptor binding. This is consistent with the low levels of nonspecific binding (Ͻ5%) as defined by doses of flunitrazepam that saturate the binding site and is in agreement with previous work (Potier et al. 1988a; Facklam et al. 1992) . Taken together, these data demonstrate the utility of [ 3 H]Ro 15-1788 as a radioligand with which to study benzodiazepine binding sites in vivo (Goeders and Kuhar 1985; Potier et al. 1988b) .
The nonselective compounds diazepam, flunitrazepam, and DMCM, all of which have comparable affinities at different ␣ subunit-containing GABA A receptors, had essentially the same ID 50 for the displacement of [ 3 H]Ro 15-1788 in cerebellum and spinal cord (Figure 3) . A similar lack of regional selectivity for diazepam and flunitrazepam has been reported previously in various regions of the mouse (Potier et al. 1988b ) and rat (Benavides et al. 1992 However, the ID 50 for diazepam observed in the present study (2 mg/kg) is appreciably lower than previous estimates (10 mg/kg, Benavides et al. 1988) .
Concerning ␣ 1 selective compounds, the in vitro selectivity of CL 218,872 and zolpidem for ␣ 1 versus ␣ 2 and ␣ 3 subunit-containing recombinant GABA A receptors (Figure 1 ) was reflected by a preferential in vivo occupancy of cerebellum versus spinal cord (␣ 1 and ␣ 2 /␣ 3 subunit-containing tissues, respectively) benzodiazepine binding sites. Thus, lower doses of these ␣ 1 -selective compounds were required to inhibit 50% of the in vivo binding of [ 3 H]Ro 15-1788 in cerebellum compared to spinal cord. A comparable selectivity of in vivo binding has also been observed in mouse cerebellum versus cortex or hippocampus (Potier et al. 1988b ) and in rat cerebellum versus spinal cord (Benavides et al. 1992) . In addition, autoradiographic studies of in vivo [
3 H]Ro 15-1788 binding showed that the ID 50 of zolpidem in a number of ␣ 1 subunit-containing brain regions was appreciably lower than in regions with a more heterogeneous distribution of GABA A receptor subtypes (Benavides et al. 1988 Potier et al. 1988b ) and for zolpidem in autoradiographic analysis of mouse cerebellum (3.6 mg/kg; Benavides et al. 1988 ). This degree of selectivity is also observed in the rat where respective ID 50 values for cerebellum and spinal cord were 6 and 19 mg/kg for CL 218,872 and 7 and Ͼ100 mg/kg for zolpidem (Benavides et al. 1992) , although direct comparisons between effective doses in mice and rats is complicated by the possible species differences in pharmacokinetics (e.g., bretazenil, Martin et al. 1988) .
It should be noted that the differences in the cerebellum and spinal cord ID 50 values for the reduction in in vivo [
3 H]Ro 15-1788 binding by CL 218,872 and zolpidem are generally less than the ␣ 1 selectivity of these compounds in vitro. For example, CL 218,872 had ID 50 values of 4.5 and 12 mg/kg-an in vivo selectivity of less than threefold-whereas, the affinity of this compound at ␣ 1 subunit containing receptors in vitro is 20-and 35-fold higher than for ␣ 2 and ␣ 3 subunitcontaining receptors, respectively. It is possible that this difference between in vitro affinity and in vivo potency could be attributable to different drug levels in the cerebellum and spinal cord. However, levels of zolpidem did not differ in rat cerebellum and spinal cord (Benavides et al. 1992) , although this does not preclude the possibility of regional variations in CL 218,872 levels. The reason for this discrepancy between in vitro affinity and in vivo potency at ␣ 1 versus ␣ 2 /␣ 3 receptors in unclear but underscores the need to establish in vivo occupancy of subtype selective compounds to rationalize the behavioral properties of such drugs.
Compounds acting at the benzodiazepine site of the GABA A receptor produce a range of behavioral effects. The identification of subtypes of the GABA A receptor with distinct pharmacological and structural properties along with discrete neuroanatomical localizations has lead to the hypothesis that compounds that selectively interact with only some of these subtypes might possess only part of the range of effects associated with the nonselective benzodiazepines (Doble and Martin 1992) . In addition to the in vivo occupancy, a further factor to be considered in understanding the mechanisms underlying the behavioral properties of a compound is the intrinsic efficacy of that compound (Facklam et al. 1992) . Thus, for example, although compounds such as CL 218,872 and zolpidem selectively interact with the benzodiazepine site of ␣ 1 subunit-containing GABA A receptors, their different efficacies (partial and full agonists, respectively) results in distinct behavioral profiles ( Lüddens et al. 1995) . In this respect, the inhibition of in vivo binding of [ 3 H]benzodiazepines has proved to be crucial in unraveling the relationships between the degree of receptor occupancy required by compounds of varying intrinsic efficacies to produce distinct behavioral effects (Duka et al. 1979; Benavides et al. 1988 Benavides et al. , 1992 Facklam et al. 1992; Giusti et al. 1993; Martin et al. 1993; Jones et al. 1994 ).
The problems of interpreting behavioral data in terms of receptor occupancy and intrinsic efficacy is given an added dimension when considering attributing distinct behavioral properties to compounds that selectively interact with particular GABA A receptor subtypes. In this regard, the fact that the occupancy of benzodiazepine binding sites in regions expressing different GABA A receptor populations reflects their in vitro binding affinity suggests that the displacement of in vivo [
3 H]Ro 15-1788 binding in cerebellum and spinal cord should prove to be a valuable tool in unraveling the complexities of the behavioral profiles of ␣ 1 or ␣ 2 /␣ 3 subtype-selective compounds.
